Click here to close now.

Welcome!

News Feed Item

Easton Pharmaceuticals Finalizing Investment Terms in Private Medical Marijuana Device Company; Moves to Initiate Legal Action Against Libelous Seeking Alpha Article

TORONTO, ON -- (Marketwired) -- 06/25/14 -- Easton Pharmaceuticals Inc. (OTC: EAPH) is near final agreement with a medical marijuana technology company specializing in controlled environment agricultural technologies.

Easton Pharmaceuticals, following due diligence, is moving towards investing in medical marijuana device technology and agricultural product. The investment objective manufactures products designed to ensure that medical marijuana cultivation, bottling, edibility, extract manufacturing and dispensaries maintain the highest quality of food safety standards for antimicrobial and bacteria free facilities. Easton's management believes this great investment opportunity will meet strong industry demand and generate positive revenues which will be highlighted in greater detail following a closing agreement. This investment coincides with the company's over-the-counter delivery technology products including Viorra, a non-invasive topical treatment intended to assist women suffering from a range of Female Sexual Arousal Disorders (FSAD).

Easton, in addition to Viorra, maintains a minority ownership in the early stage cancer drug Xilive which is near finalizing on a deal to have this position vastly increased due to positive responses from patent attorneys. Added to these products and initiatives is a 50% ownership in the early stage drug for the treatment of female sexual arousal disorder. The company's medical marijuana initiatives alongside Viorra are deemed to be the best short term options as excellent potential revenue producers. Easton still maintains discussions with third party partners to open a medical marijuana dispensary(s) in certain counties and jurisdictions within the State of Michigan.

An update to Easton's medical marijuana grower's license initiative within the country of Canada is anticipated to be the company's upcoming announcement.

In other developments, Easton Pharmaceuticals is moving towards taking action against libelous statements made by multiple online sources, in particular Seeking Alpha. The article published March 18, 2014 was written by a Matt Finston who made inaccurate and libelous statements attacking Easton's trading stock. Easton is now taking action against Finston after the company's progress on its medical marijuana initiatives and its wholehearted attempt to give Mr. Finston the benefit of the doubt prior to legal action to allow a retraction of certain statements proved fruitless. The article makes several false and misleading statements about Easton, its product line and history as well as allegations that the company was part of a pump and dump scheme a year earlier which are completely false and libelous. Easton Pharmaceuticals has retained counsel to pursue to the fullest extent of the law Mr. Finston and anyone who affiliated with, encouraged or directed his assignment. Mr. Finston's libelous article has damaged the company with not only market cap but with discussions it was having with other third parties.

Easton's management contacted Mr. Finston about misstating that the company tried to sell Viorra in 1998 when, in actuality, the product's acquisition date was 2009. This writer then changed only the date but made no retraction of any type nor any attempted apologies for the grievous mistake. Mr. Finston then alleged that Easton issued restricted shares a year prior for the purpose of planning a pump and dump with Global links. Management has never issued any shares for pump and dump schemes and it should be noted that those shares belonged to a senior consultant by the name of Mr. Neil Mellor, have yet to be and will never be deposited due to a conflict of interest with Mr. Mellor and his company. This was a defamatory statement which was supposed to be retracted once facts, other inaccuracies and judgments were made clear. This has not happened. Mr. Finston also stated the company was unavailable for comment even though no calls were received. Since his article, Easton has made several requests for Mr. Finston to contact and speak with Easton's management and consultants. However, he has refused to respond to all phone call requests, thus contradicting his own statements. The article's release was at or near the company's peak common stock price, which was followed by countless negative and defamatory postings on several web investor portals namely Investorhub, which continue to this day.

Carla Pepe, CEO of Easton Pharmaceuticals, stated: "We are currently exploring all of our legal options for relief. In addition we believe this to be part of a larger orchestrated effort to short Easton Pharmaceuticals stock so individuals can illegally profit from the company's decline. The company is not against the practice of shorting stocks, but is vehemently against anyone posting inaccurate and defamatory statements to achieve their goals. We are in the process of alerting the regulatory bodies about the events and have instructed counsel to take action against Mr. Finston and any others involved. Our company is doing its utmost to grow its business and enter into certain business segments that can ultimately allow the company to be successful and positive revenue generating. We believe we have a tremendous opportunity ahead in the medical cannabis sector coinciding with our other products and businesses. We remain dedicated to executing our business plan and look forward to updating investors on new and potentially significant milestones for the company as the quarter and first half of the year comes to a close later this month."

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company is also endeavoring to enter other potentially lucrative industries such as medical marijuana. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' product "VIORRA" is an over-the-counter, topical daily use product and aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder); the world market for these female conditions is conservatively estimated to be in the billions.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. There are no guarantees or assurances that any proposals, initiatives or negotiations will result in what the company had originally intended. Any investment made into Easton Pharmaceuticals would be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
SYS-CON Events announced today that Harbinger Systems will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Harbinger Systems is a global company providing software technology services. Since 1990, Harbinger has developed a strong customer base worldwide. Its customers include software product companies ranging from hi-tech start-ups in Silicon Valley to leading product companies in the US a...
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult – let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and liv...
In his session at 16th Cloud Expo, Simone Brunozzi, VP and Chief Technologist of Cloud Services at VMware, reviewed the changes that the cloud computing industry has gone through over the last five years and shared insights into what the next five will bring. He also chronicled the challenges enterprise companies are facing as they move to the public cloud. He delved into the "Hybrid Cloud" space and explained why every CIO should consider ‘hybrid cloud' as part of their future strategy to achie...
DevOps Summit, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development...
"A lot of the enterprises that have been using our systems for many years are reaching out to the cloud - the public cloud, the private cloud and hybrid," stated Reuven Harrison, CTO and Co-Founder of Tufin, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
The time is ripe for high speed resilient software defined storage solutions with unlimited scalability. ISS has been working with the leading open source projects and developed a commercial high performance solution that is able to grow forever without performance limitations. In his session at Cloud Expo, Alex Gorbachev, President of Intelligent Systems Services Inc., shared foundation principles of Ceph architecture, as well as the design to deliver this storage to traditional SAN storage co...
The last decade was about virtual machines, but the next one is about containers. Containers enable a service to run on any host at any time. Traditional tools are starting to show cracks because they were not designed for this level of application portability. Now is the time to look at new ways to deploy and manage applications at scale. In his session at @DevOpsSummit, Brian “Redbeard” Harrington, a principal architect at CoreOS, will examine how CoreOS helps teams run in production. Attende...
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at th...
In the midst of the widespread popularity and adoption of cloud computing, it seems like everything is being offered “as a Service” these days: Infrastructure? Check. Platform? You bet. Software? Absolutely. Toaster? It’s only a matter of time. With service providers positioning vastly differing offerings under a generic “cloud” umbrella, it’s all too easy to get confused about what’s actually being offered. In his session at 16th Cloud Expo, Kevin Hazard, Director of Digital Content for SoftL...
Live Webinar with 451 Research Analyst Peter Christy. Join us on Wednesday July 22, 2015, at 10 am PT / 1 pm ET In a world where users are on the Internet and the applications are in the cloud, how do you maintain your historic SLA with your users? Peter Christy, Research Director, Networks at 451 Research, will discuss this new network paradigm, one in which there is no LAN and no WAN, and discuss what users and network administrators gain and give up when migrating to the agile world of clo...
17th Cloud Expo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises ar...
Agile, which started in the development organization, has gradually expanded into other areas downstream - namely IT and Operations. Teams – then teams of teams – have streamlined processes, improved feedback loops and driven a much faster pace into IT departments which have had profound effects on the entire organization. In his session at DevOps Summit, Anders Wallgren, Chief Technology Officer of Electric Cloud, will discuss how DevOps and Continuous Delivery have emerged to help connect dev...
"We help to transform an organization and their operations and make them more efficient, more agile, and more nimble to move into the cloud or to move between cloud providers and create an agnostic tool set," noted Jeremy Steinert, DevOps Services Practice Lead at WSM International, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
SYS-CON Events announced today that Secure Infrastructure & Services will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Secure Infrastructure & Services (SIAS) is a managed services provider of cloud computing solutions for the IBM Power Systems market. The company helps mid-market firms built on IBM hardware platforms to deploy new levels of reliable and cost-effective computing and hig...
"AgilData is the next generation of dbShards. It just adds a whole bunch more functionality to improve the developer experience," noted Dan Lynn, CEO of AgilData, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.